<DOC>
	<DOCNO>NCT00145327</DOCNO>
	<brief_summary>This extension study design assess long term safety efficacy zoledronic acid postmenopausal woman osteoporosis participate CZOL446H2301 ( NCT00049829 ) : HORIZON Pivotal Fracture Trial . This extension study begin 3-year core study end . Baseline Year 3 .</brief_summary>
	<brief_title>Double-blind Extension HORIZON Pivotal Fracture Trial ( Zoledronic Acid Treatment Postmenopausal Osteoporosis )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients receive 3 infusion HORIZONPivotal Fracture ( PFT ) Study . Poor kidney , eye , liver health Use certain therapy osteoporosis HORIZONPFT study ( study medication ) Abnormal calcium level blood Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>68 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Osteoporosis , Zoledronic Acid</keyword>
</DOC>